Drug Profile

SYHX 2011

Alternative Names: SYHX-2011

Latest Information Update: 12 Apr 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

12 Apr 2024 CSPC Ouyi Pharmaceutical plans a phase II trial for Breast Cancer (Late-stage disease) in China in April 2024 (IV, Infusion)(NCT06354114)
03 Mar 2023 CSPC Ouyi Pharmaceutical plans a phase III trial for Breast cancer (Late-stage disease) in China in May 2023 (IV, Infusion) (NCT05753865)
11 Mar 2022 CSPC Ouyi Pharmaceutical plans a phase I trial for Breast cancer (Late-stage disease) in March 2022 (IV, Infusion) (NCT05274893)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com